Abstract

The evaluation of drug–polymer miscibility in the early phase of drug development is essential to ensure successful amorphous solid dispersion (ASD) manufacturing. This work investigates the comparison of thermodynamic models, conventional experimental screening methods (solvent casting, quench cooling), and a novel atomization screening device based on their ability to predict drug–polymer miscibility, solid state properties (Tg value and width), and adequate polymer selection during the development of spray-dried amorphous solid dispersions (SDASDs). Binary ASDs of four drugs and seven polymers were produced at 20:80, 40:60, 60:40, and 80:20 (w/w). Samples were systematically analyzed using modulated differential scanning calorimetry (mDSC) and X-ray powder diffraction (XRPD). Principal component analysis (PCA) was used to qualitatively assess the predictability of screening methods with regards to SDASD development. Poor correlation was found between theoretical models and experimentally-obtained results. Additionally, the limited ability of usual screening methods to predict the miscibility of SDASDs did not guarantee the appropriate selection of lead excipient for the manufacturing of robust SDASDs. Contrary to standard approaches, our novel screening device allowed the selection of optimal polymer and drug loading and established insight into the final properties and performance of SDASDs at an early stage, therefore enabling the optimization of the scaled-up late-stage development.

Highlights

  • New chemical entities with unfavorable water solubility properties are continuously emerging from high-throughput screening during the drug discovery phase in the pharmaceutical industry [1]

  • 70.8 a: Values calculated based upon the range of substituent proportion on glucose ring found in supplier literature. b: Block copolymer: n = 0.6 and m = 0.4. c: Block copolymer: n = 0.57, m = 0.3, and l = 0.13. d: Block copolymer: n = 0.5 and m = 0.5

  • The phase behavior of amorphous solid dispersion (ASD) is influenced by formulation and process factors such as polymer choice, drug loading (DL), solvent/solvent-free preparation method, solvent evaporation rate, and final nature of product

Read more

Summary

Introduction

New chemical entities with unfavorable water solubility properties are continuously emerging from high-throughput screening during the drug discovery phase in the pharmaceutical industry [1]. Amorphous solid dispersions (ASDs) have become a common formulation strategy to increase the bioavailability of poorly water soluble compounds (class II&IV) [3]. ASDs were initially defined by Chiou and Riegelman (1971) as “a dispersion of one or more active ingredients in an inert carrier at the solid state, prepared by the melting, the solvent, or the melting solvent method” [4]. The improvement of dissolution rate is mainly correlated to the increase of specific surface area and the decrease of diffusion layer thickness of the formulation. These characteristics are respectively induced by the generated porosity, drug particle size reduction, and improved wettability [5]. Among the solvent-based technologies, spray drying is a suitable and scalable process for ASD production from laboratory to commercial scale [7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call